论文部分内容阅读
近年来,肿瘤免疫冶疗的研究之特点为多学科交叉渗透及多部门共同参与.因而,分子免疫学、分子生物学、分子遗传学及相关生物学高技术的结合,为肿瘤免疫治疗奠定了重要的分子基础.1 肿瘤特异性表位的研究进展肿瘤免疫治疗是肿瘤生物治疗的重要基础,那么寻找肿瘤特异性抗原必然是肿瘤免疫治疗的关键.从50年代Gross等发现TSTA,到90年代T.Boon证实人类第一个肿瘤抗原表位,为肿瘤特异性免疫治疗打下了坚实的基础.但是迄今为止被发现的有限肿瘤特异性抗原,使得众多肿瘤学家仍然孜孜不倦地挖掘新的肿瘤持异性抗原(表位).目前采用的主要技术路线有:
In recent years, the research of tumor immunotherapy has been characterized by multi-disciplinary cross-infiltration and multi-sector participation. Therefore, the combination of molecular immunology, molecular biology, molecular genetics, and related biological high technologies has laid the foundation for cancer immunotherapy. Important Molecular Basis.1 Research Progress of Tumor-specific Epitopes Tumor immunotherapy is an important basis for cancer biological therapy, so finding tumor-specific antigens must be the key to tumor immunotherapy. From the 50’s Gross et al. discovered TSTA to the 1990s. T. Boon confirmed the first human tumor antigen epitope and laid a solid foundation for tumor-specific immunotherapy. However, the limited tumor-specific antigens discovered so far have made many oncologists still tirelessly tap new tumors. Heteroantigen (epitope). The main technical routes currently used are: